STOCK TITAN

Organigram Global gets Nasdaq US$1 bid-price notice

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Organigram Global Inc. (OGI) received a Nasdaq notice after its common shares’ closing bid price remained below US$1.00 per share for 30 consecutive business days, failing to meet Nasdaq’s minimum bid-price requirement. The notice has no immediate effect on listing or trading on Nasdaq. Organigram has 180 calendar days, through May 10, 2027, to regain compliance by maintaining a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days; Nasdaq may extend that period.

If Organigram does not regain compliance by May 10, 2027, it may be eligible for an additional 180-calendar-day period, subject to Nasdaq’s requirements, including transferring its listing to the Nasdaq Capital Market. If it does not qualify for an additional period, its shares may become subject to delisting proceedings, subject to applicable appeal rights. The notice does not affect Organigram’s Toronto Stock Exchange listing or compliance status.

Minimum bid price US$1.00 per share Nasdaq’s continued-listing requirement
Time below minimum bid price 30 consecutive business days Period that triggered the Nasdaq deficiency notice
Compliance period 180 calendar days Period to regain compliance, through May 10, 2027
Compliance deadline May 10, 2027 End of the initial compliance period
Required compliance streak 10 consecutive business days Closing bid price must be at least US$1.00 per share
Potential additional compliance period 180 calendar days May be available subject to applicable Nasdaq requirements
Minimum Bid Requirement regulatory
"minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”)"
A minimum bid requirement is a rule that a stock’s price must meet or exceed a set floor for certain market actions — for example to remain listed on an exchange, qualify for a tender offer, or participate in a specific auction. It matters to investors because falling below that floor can trigger delisting, limit who can buy or sell the shares, or change the terms of a transaction; think of it like a store’s minimum purchase needed to access a special sale, which affects value and liquidity.
compliance period regulatory
"180 calendar days, until May 10, 2027, to regain compliance"
A compliance period is a defined stretch of time during which a company must meet specific legal, regulatory, or contractual rules and reporting requirements. Think of it like a scheduled inspection window or a homework deadline: failing to satisfy the rules within that window can trigger fines, restrictions, or extra oversight, so investors watch compliance periods as signals of near-term legal risk, potential costs, and impacts on a company’s operations or cash flow.
delisting proceedings regulatory
"may become subject to delisting proceedings"
Delisting proceedings are the formal steps taken to remove a company’s shares from a stock exchange, either because the company chose to leave or failed to meet rules like minimum share price, reporting or solvency requirements. For investors this matters because removal usually cuts trading access and liquidity, can sharply lower the share price, and makes it harder to buy, sell or get transparent information — similar to a product being pulled off supermarket shelves.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did OGI receive a Nasdaq minimum bid notice?

Nasdaq said Organigram’s common-share closing bid price was below US$1.00 per share for 30 consecutive business days, triggering a deficiency under its minimum bid-price requirement.

What must OGI do to regain Nasdaq compliance?

Organigram must maintain a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days during its compliance period. The 180-calendar-day period runs through May 10, 2027, and Nasdaq may extend it.

Does the OGI Nasdaq notice affect its TSX listing or trading?

The notice has no immediate effect on the listing or trading of Organigram’s common shares on Nasdaq. It does not affect the company’s Toronto Stock Exchange listing or compliance status.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-38885
ORGANIGRAM GLOBAL INC.
(Translation of registrant’s name into English)

145 King Street West, Suite 1400
Toronto, Ontario ,Canada M5H 1J8
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ]           Form 40-F [ X ]




SUBMITTED HEREWITH

Exhibits
99.1
News Release dated November 13, 2026



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ORGANIGRAM GLOBAL INC.






/s/ Greg Guyatt
Greg Guyatt
Chief Financial Officer

Date: November 13, 2026







Organigram Provides NASDAQ Listing Update
The Notification has no immediate effect on the listing or trading of the Company's common shares on the Nasdaq Global Select Market.
TORONTO, ON, November 13, 2026 – Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the “Company” or “Organigram”), Canada's #1 cannabis company by market share¹ and a growing global cannabis platform, today announced that on November 11, 2026, it received notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Select Market. The Notification was issued because the closing bid price of the Company's common shares was below US$1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5450(a)(1) requires listed common shares to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”), while Nasdaq Listing Rule 5810(c)(3)(A) provides that a deficiency exists when the requirement is not met for 30 consecutive business days.
The Notification has no immediate effect on the listing or trading of the Company's common shares on the Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, until May 10, 2027, to regain compliance with the Minimum Bid Requirement. To regain compliance, the closing bid price of the Company's common shares must be at least US$1.00 per share for a minimum of 10 consecutive business days during the compliance period, subject to Nasdaq's discretion to extend this period.
If the Company does not regain compliance by May 10, 2027, it may be eligible for an additional 180-calendar-day compliance period, subject to satisfying applicable Nasdaq requirements, including transferring its listing to the Nasdaq Capital Market. If the Company does not qualify for an additional compliance period, its common shares may become subject to delisting proceedings, subject to applicable appeal rights.
The Company's common shares are also listed on the Toronto Stock Exchange, and the Notification does not affect the Company's listing or compliance status on that exchange.
About Organigram
Organigram Global Inc. is listed on the NASDAQ Global Select Market and TSX. The Company's wholly owned subsidiary, Organigram Inc., is a licensed cultivator and processor. Through its acquisition of Sanity Group GmbH ("Sanity Group"), Organigram participates in the German medical cannabis market and other emerging markets within Europe. Organigram is focused on producing high-quality cannabis for adult consumers, as well as extending the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, ZOIKS, Endosane Pharmaceuticals,



VAAY, and Grashaus Projects. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.
Contacts
For Investor enquiries:

Max Schwartz, Director of Investor Relations
investors@organigram.ca

Filing Exhibits & Attachments

1 document

Keep reading